MARKSANS

MARKSANS PHARMA

Small Cap BSE: 524404 NSE: MARKSANS
₹46.65
0.2 (0.43%)
As on 30 September, 2022 | 01:51

Marksans Pharma Share Price

Marksans Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in MARKSANS PHARMA

Start SIP

Marksans Pharma Share Returns

  • Over 1 Month -10.63%
  • Over 3 Month 9.89%
  • Over 6 Month 0.43%
  • Over 1 Year -31.75%

Marksans Pharma Key Statistics

P/E Ratio 10.4
PEG Ratio -0.4
Market Cap Cr 1,909
Price to Book Ratio 1.6
EPS 2.5
Dividend 0.5
Relative Strength Index 27.91
Money Flow Index 9.73
MACD Signal -0.39
Average True Range 1.47

Marksans Pharma Investment Rating

  • Master Rating:
  • Marksans Pharma has an operating revenue of Rs. 1,575.64 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 17% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Marksans Pharma Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 159176166169147138
Operating Expenses Qtr Cr 148149138135122111
Operating Profit Qtr Cr 122728342527
Depreciation Qtr Cr 555444
Interest Qtr Cr 111112
Tax Qtr Cr 679959
Net Profit Qtr Cr 192126282924

Marksans Pharma Technicals

EMA & SMA

Current Price
46.65
0.2 (0.43%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 49.9
  • 50 Day
  • 50.14
  • 100 Day
  • 50.15
  • 200 Day
  • 51.51
  • 20 Day
  • 51
  • 50 Day
  • 50.68
  • 100 Day
  • 48.35
  • 200 Day
  • 51.48

Marksans Pharma Resistance and Support

PIVOT
₹46.69
Resistance
First Resistance 47.17
Second Resistance 47.89
Third Resistance 48.37
RSI 27.91
MFI 9.73
MACD Single Line -0.39
MACD -1.12
Support
First Resistance 45.97
Second Resistance 45.49
Third Resistance 44.77

Marksans Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 929,295 63,080,545 67.88
Week 855,086 54,836,691 64.13
1 Month 811,364 48,738,635 60.07
6 Month 1,321,317 52,205,247 39.51

Marksans Pharma Result Highlights

Marksans Pharma Synopsis

NSE-Medical-Diversified

Marksans Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 658.29 Cr. and Equity Capital is Rs. 40.93 Cr. for the Year ended 31/03/2022. Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364.
Market Cap 1,909
Sales 670
Shares in Float 21.28
No of funds 57
Yield 0.54
Book Value 2.43
U/D Vol ratio 0.7
LTDebt / Equity
Alpha -0.12
Beta 1.19

Marksans Pharma

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 48.25%48.25%48.25%
Mutual Funds 0.95%0.46%0.34%
Foreign Portfolio Investors 4.04%3.46%2.59%
Financial Institutions/ Banks
Individual Investors 40.77%41.35%42.47%
Others 5.99%6.48%6.35%

Marksans Pharma Management

Name Designation
Mr. Mark Saldanha Chairman & Managing Director
Mrs. Sandra Saldanha Whole Time Director
Mr. Varddhman V Jain Whole Time Director
Dr. Sunny Sharma Non Executive Director
Mr. Digant Mahesh Parikh Independent Director
Mr. Abhinna Sundar Mohanty Independent Director
Mr. Seetharama R Buddharaju Independent Director
Dr.(Mrs.) Meena Rani Surana Independent Director

Marksans Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Marksans Pharma Corporate Action

Date Purpose Remarks
2022-08-13 Quarterly Results
2022-07-08 Buy Back of shares
2022-05-30 Audited Results & Final Dividend
2022-02-11 Quarterly Results
2021-11-10 Quarterly Results (Revised) per share(5%)Dividend

Marksans Pharma MF Shareholding

Name Amount(cr)
Quant Small Cap Fund Growth 2079
Motilal Oswal S&P BSE Healthcare ETF 6

Marksans Pharma FAQs

What is Share Price of Marksans Pharma ?

Marksans Pharma share price is ₹46 As on 30 September, 2022 | 01:37

What is the Market Cap of Marksans Pharma ?

The Market Cap of Marksans Pharma is ₹1909.4 Cr As on 30 September, 2022 | 01:37

What is the P/E ratio of Marksans Pharma ?

The P/E ratio of Marksans Pharma is 10.4 As on 30 September, 2022 | 01:37

What is the PB ratio of Marksans Pharma ?

The PB ratio of Marksans Pharma is 1.6 As on 30 September, 2022 | 01:37

Q1FY23